Holen Sie sich die Stockscreener-App
135.93
3.65%
4.79
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$131.14
Offen:
$131.26
24-Stunden-Volumen:
13.18M
Relative Volume:
1.92
Marktkapitalisierung:
$168.65B
Einnahmen:
$29.05B
Nettoeinkommen (Verlust:
$8.11B
KGV:
21.05
EPS:
6.4563
Netto-Cashflow:
$9.16B
1W Leistung:
+8.82%
1M Leistung:
+8.58%
6M Leistung:
+19.70%
1J Leistung:
+46.29%
1-Tages-Spanne:
$131.00
$136.30
1-Wochen-Bereich:
$122.28
$136.30
52-Wochen-Spanne:
$92.26
$136.30
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
135.93 | 162.70B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,064.29 | 973.23B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
220.14 | 526.41B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
219.26 | 385.48B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
147.14 | 278.22B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.26 | 276.52B | 46.69B | 15.29B | 9.25B | 3.4329 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences, Inc. $GILD is Sector Gamma AS's 9th Largest Position - MarketBeat
First Citizens Bank & Trust Co. Purchases 61,959 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
AMF Tjanstepension AB Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Mn Services Vermogensbeheer B.V. Acquires 8,500 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Resona Asset Management Co. Ltd. - MarketBeat
Gilead Sciences, Inc. $GILD Stake Increased by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
UniSuper Management Pty Ltd Has $62.38 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Teacher Retirement System of Texas Has $36.91 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by Envestnet Portfolio Solutions Inc. - MarketBeat
Gilead Sciences (NASDAQ:GILD) Downgraded by Wall Street Zen to Buy - MarketBeat
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM - TechStock²
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM - TechStock²
MOKAN Wealth Management Inc. Trims Position in Gilead Sciences, Inc. $GILD - MarketBeat
Strs Ohio Purchases 24,284 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Rakuten Investment Management Inc. Purchases New Shares in Gilead Sciences, Inc. $GILD - MarketBeat
Grandfield & Dodd LLC Sells 20,655 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
iA Global Asset Management Inc. Raises Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Movement Recap: Is Gilead Sciences Inc trading at a discount2025 Market Sentiment & Stepwise Trade Signal Guides - baoquankhu1.vn
Why Gilead Sciences (GILD) Outpaced the Stock Market Today - Yahoo Finance
4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer - GlobeNewswire Inc.
Gilead Sciences publishes Trodelvy-Keytruda data in NEJM - The Pharma Letter
Cell Therapy Market Dynamics and Contributions by Gilead - openPR.com
Gilead Sciences Inc. (NASDAQ:GILD) Passes the Caviar Cruise Quality Investing Screen - Chartmill
Jeffrey Bluestone Sells 5,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
GILD: Gilead Sciences Reports Positive Results for Trodelvy and Keytruda Combo - GuruFocus
Gilead Sciences (NASDAQ:GILD) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
Gilead Sciences stock hits all-time high at 128.71 USD By Investing.com - Investing.com Nigeria
Gilead Sciences stock hits all-time high at 128.71 USD - Investing.com
Rothschild & Co Redburn Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Gilead Sciences (GILD) Valuation Check After Recent Share Price Softness - Yahoo Finance
Universal Beteiligungs und Servicegesellschaft mbH Lowers Position in Gilead Sciences, Inc. $GILD - MarketBeat
Migdal Insurance & Financial Holdings Ltd. Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
US Stocks Recap: What is the PEG ratio of Gilead Sciences IncPrice Action & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Gilead Sciences: Margin Expansion And Cash Flow Strength Underpriced (NASDAQ:GILD) - Seeking Alpha
The Truth About Gilead Sciences Inc: Why Everyone Is Suddenly Watching This Stock - AD HOC NEWS
Bernstein reiterates Outperform rating on Gilead stock with $135 price target - Investing.com
Gilead Sciences, Inc. $GILD Shares Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat
Royal Bank Of Canada Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
40 Under 40: Calvin Yan Ting Chan, Gilead Sciences - Medical Marketing and Media
Stocks Generating Improved Relative Strength: Gilead Sciences - Investor's Business Daily
Gilead Sciences Earnings Outlook: Key Points to Watch - Bitget
Lobbying Update: $30,000 of TIBER CREEK GROUP ON BEHALF OF GILEAD SCIENCES INC. lobbying was just disclosed - Quiver Quantitative
Gilead Sciences Earnings Preview: What to Expect - Barchart.com
Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Allstate Corp Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Nasdaq Futures Spotlight Biopharma Scale - Kalkine Media
Csenge Advisory Group Has $2.38 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Campbell & CO Investment Adviser LLC Invests $1.40 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by QRG Capital Management Inc. - MarketBeat
HER2-Negative Metastatic Breast Cancer Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai - Barchart.com
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):